S&P 500
$5,842.01
-0.0%
-$2.60
DJI
41,859.09
-0.0%
-1.35
NASDAQ
$18,925.73
+0.3%
+$53.09
Bitcoin
111,215.00
+1.5%
+1,595.23
AAPL
$201.16
-0.5%
-$0.93
AMZN
$202.96
+0.9%
+$1.84
GOOG
$171.96
+1.1%
+$1.90
META
$636.81
+0.2%
+$1.31
MSFT
$454.60
+0.4%
+$2.03
NVDA
$132.90
+0.8%
+$1.10
TSLA
$341.59
+2.1%
+$6.97
Immatics (NASDAQ: IMTX)
$5.23
(2.1%)
$0.11
Price as of May 22, 2025, 3:58 p.m. ET
Immatics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Immatics Company Info
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline include adoptive cell therapy and TCR Bispecifics.The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
News & Analysis
Featured Article
Why Immatics Stock Is Soaring Today
Investors liked what they heard in Immatics' interim results for experimental immunotherapy IMA203.
Keith Speights | May 2, 2023
Featured Article
Why Immatics Stock Is Soaring Today
Investors liked the company's latest clinical update.
Prosper Junior Bakiny | Mar 17, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.